The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1620
ISSUE 1620
March 24, 2021
Stiripentol (Diacomit) for Dravet Syndrome (online only)
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
March 24, 2021 (Issue: 1620)
The FDA has approved stiripentol (Diacomit – Biocodex)
for treatment of seizures in patients ≥2 years old with
Dravet syndrome who are also taking clobazam (Onfi).
Stiripentol, which has been available in Europe, Canada,
and Japan for many years, is the second drug to be
approved in the US for this indication; cannabidiol oral
solution (Epidiolex), a purified marijuana product, was
the first.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Stiripentol (Diacomit) for Dravet Syndrome (online only)
Article code: 1620c
Electronic, downloadable article - $45
Article code: 1620c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
